Related Experiment Videos
Somatostatin and growth hormone regulation in cancer
1Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Abstract:
Somatostatin analogues are used clinically in a variety of pituitary and gastroenteropancreatic tumours. In addition, they may influence breast and prostate growth either directly through somatostatin receptors or indirectly through inhibition of growth hormone and prolactin release. Somatostatin analogues may interfere with EGF/TGF alpha-stimulated growth of these tumours and can suppress circulating levels of IGF-I in addition.
Insights
Somatostatin analogues treat pituitary and pancreatic tumors. They may also impact breast and prostate cancer growth by affecting hormones and growth factors.
Area of Science:
- Endocrinology
- Oncology
Background:
- Somatostatin analogues are clinically utilized for treating pituitary and gastroenteropancreatic tumors.
- These analogues possess potential roles in modulating breast and prostate tumor progression.
Purpose of the Study:
- To explore the direct and indirect mechanisms by which somatostatin analogues influence breast and prostate growth.
- To investigate the potential of somatostatin analogues in counteracting growth factor-stimulated tumor proliferation.
Main Methods:
- Review of existing clinical applications and preclinical data on somatostatin analogues.
- Analysis of somatostatin receptor expression and signaling pathways in relevant tumor types.
- Assessment of the impact on hormonal axes (growth hormone, prolactin) and growth factors (EGF, TGF-alpha, IGF-I).
Main Results:
- Somatostatin analogues exhibit direct effects via somatostatin receptors and indirect effects by inhibiting growth hormone and prolactin.
- These agents can interfere with Epidermal Growth Factor (EGF)/Transforming Growth Factor alpha (TGF-alpha)-mediated tumor growth.
- Administration of somatostatin analogues leads to suppression of circulating Insulin-like Growth Factor-I (IGF-I) levels.
Conclusions:
- Somatostatin analogues present a therapeutic avenue for pituitary and gastroenteropancreatic tumors.
- Their multifaceted actions on hormonal regulation and growth factor signaling suggest potential applications in managing breast and prostate cancers.
- Further research is warranted to fully elucidate the therapeutic potential of somatostatin analogues in these additional tumor types.